Disease-modifying treatment of Parkinson’s disease by phytochemicals: targeting multiple pathogenic factors

被引:0
作者
Makoto Naoi
Wakako Maruyama
Masayo Shamoto-Nagai
机构
[1] Aichi Gakuin University,Department of Health and Nutrition, Faculty of Psychological and Physical Science
来源
Journal of Neural Transmission | 2022年 / 129卷
关键词
Parkinson’s disease; Phytochemicals; Neuroprotection; Mitochondria; α-Synuclein;
D O I
暂无
中图分类号
学科分类号
摘要
Parkinson’s disease is characterized by typical motor symptoms, loss of dopamine neurons in the substantia nigra, and accumulation of Lewy body composed of mutated α-synuclein. However, now it is considered as a generalized disease with multiple pathological features. Present available treatments can ameliorate symptoms at least for a while, but only a few therapies could delay progressive neurodegeneration of dopamine neurons. Lewy body accumulates in peripheral tissues many years before motor dysfunction becomes manifest, suggesting that disease-modifying therapy should start earlier during the premotor stage. Long-termed regulation of lifestyle, diet and supplement of nutraceuticals may be possible ways for the disease-modification. Diet can reduce the incidence of Parkinson’s disease and phytochemicals, major bioactive ingredients of herbs and plant food, modulate multiple pathogenic factors and exert neuroprotective effects in preclinical studies. This review presents mechanisms underlying neuroprotection of phytochemicals against neuronal cell death and α-synuclein toxicity in Parkinson’s disease. Phytochemicals are antioxidants, maintain mitochondrial function and homeostasis, prevent intrinsic apoptosis and neuroinflammation, activate cellular signal pathways to induce anti-apoptotic and pro-survival genes, such as Bcl-2 protein family and neurotrophic factors, and promote cleavage of damaged mitochondria and α-synuclein aggregates. Phytochemicals prevent α-synuclein oligomerization and aggregation, and dissolve preformed α-synuclein aggregates. Novel neuroprotective agents are expected to develop based on the scaffold of phytochemicals permeable across the blood–brain–barrier, to increase the bioavailability, ameliorate brain dysfunction and prevent neurodegeneration.
引用
收藏
页码:737 / 753
页数:16
相关论文
共 497 条
  • [1] Ahmed T(2016)Ginsenoside Rb1 as neuroprotective agents: a review Brain Res Bull 125 30-43
  • [2] Raza SH(2015)Curcumin pyrazole and its derivative ( Sci Rep 5 9862-101
  • [3] Maryam A(2020)-(3-nitrophenylpyrazole) curcumin inhibit aggregation, disrupt fibrils and modulate toxicity of wild type and mutant α-synuclein Front Aging Neurosci 12 103-63
  • [4] Ahsan N(2015)Resveratrol derivatives as potential treatments for Alzheimer’s and Parkinson’s disease Neurobiol Dis 74 89-1061
  • [5] Mishra S(2001)Ginsenoside Rb1 inhibits fibrillation and toxicity of alpha-synuclein and disaggregates preformed fibrils Ann Neurol 50 56-891
  • [6] Jain MK(2017)Prospective study of caffeine consumption and risk of Parkinson’s disease in men and women Clin Nutr 36 1054-1201
  • [7] Surolia A(2020)Dietary habits and neurological features of Parkinson’s disease patients: implications for practice J Parkinsons Dis 10 875-7715
  • [8] Gupta S(2015)GDNF and Parkinson’s disease: where next? A summary from a recent workshop Biochim Biophys Acta 1852 1195-211
  • [9] Arbo BD(2010)Neuroprotective action of resveratrol Proc Natl Acad Sci U S A 107 7710-1261
  • [10] Andre-Miral C(2019)EGCG remodels mature α-synuclein and amyloid-β fibrils and reduces cellular toxicity NPJ Parkinson Dis 5 8-1120